-
Sight Sciences, Inc. (SGHT) Tops Q4 EPS by 7c
-
Sight Sciences Inc. (SGHT) PT Raised to $8 at Stifel Following Optometrist Survey
-
William Blair Resumes Sight Sciences Inc. (SGHT) at Outperform
-
Sight Sciences reports 7% Q4 revenue growth to $20.4 million
-
Piper Sandler Upgrades Sight Sciences Inc. (SGHT) to Overweight, 'Dry Eye Enthusiasm Building + Improving Core Biz'
-
Sight Sciences reports positive results for OMNI glaucoma system
-
Needham Reiterates Hold Rating on Sight Sciences Inc. (SGHT)
-
Sight Sciences, Inc. (SGHT) Tops Q3 EPS by 10c ; Offers Guidance
-
Sight Sciences receives Medicare fee schedules for dry eye procedure
-
Sight Sciences study shows OMNI system reduces eye pressure long-term
-
UnitedHealthcare expands glaucoma surgery coverage to include OMNI system
-
Lake Street Capital Markets Upgrades Sight Sciences Inc. (SGHT) to Buy
-
Sight Sciences, Inc. (SGHT) Tops Q2 EPS by 3c ; Offers Guidance
-
Sight Sciences study shows TearCare system cuts dry eye treatment costs
-
Sight Sciences reports 24-month dry eye treatment durability data
-
Sight Sciences Inc. (SGHT) PT Raised to $4 at Piper Sandler
-
Needham Reiterates Hold Rating on Sight Sciences Inc. (SGHT)
-
Sight Sciences, Inc. (SGHT) Misses Q1 EPS by 5c ; Offers Guidance
-
Sight Sciences (SGHT) appoints Gary Burbach to Board
-
Sight Sciences Inc. (SGHT) PT Lowered to $4 at Stifel
-
Sight Sciences, Inc. (SGHT) Misses Q4 EPS by 1c
-
Stifel Reiterates Buy Rating on Sight Sciences Inc. (SGHT)
-
Sight Sciences Inc. (SGHT) PT Lowered to $3 at Lake Street Capital Markets
-
Sight Sciences (SGHT) Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
-
Sight Sciences (SGHT) Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System
-
UBS Starts Sight Sciences Inc. (SGHT) at Buy
-
Sight Sciences Inc. (SGHT) PT Lowered to $5.50 at Piper Sandler
-
Sight Sciences, Inc. (SGHT) Misses Q3 EPS by 1c
-
Lake Street Capital Markets Downgrades Sight Sciences Inc. (SGHT) to Hold
-
Lake Street Capital Markets Reiterates Buy Rating on Sight Sciences Inc. (SGHT)
-
Sight Sciences, Inc. (SGHT) Tops Q2 EPS by 5c, narrows guidance
-
Sight Sciences (SGHT) Gains as CMS Updates Seen as Positive

